RYTHM (NASDAQ:RYM – Get Free Report) is one of 903 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare RYTHM to similar businesses based on the strength of its risk, profitability, analyst recommendations, institutional ownership, valuation, dividends and earnings.
Profitability
This table compares RYTHM and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RYTHM | -6.20% | -12.57% | -2.60% |
| RYTHM Competitors | -2,299.87% | -222.98% | -17.45% |
Institutional and Insider Ownership
6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| RYTHM | $17.28 million | -$33.26 million | -2.44 |
| RYTHM Competitors | $3.49 billion | $3.14 billion | 545.94 |
RYTHM’s competitors have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a summary of recent ratings and price targets for RYTHM and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
| RYTHM Competitors | 7581 | 13648 | 25432 | 996 | 2.42 |
As a group, “Pharmaceuticals” companies have a potential upside of 30.13%. Given RYTHM’s competitors stronger consensus rating and higher probable upside, analysts clearly believe RYTHM has less favorable growth aspects than its competitors.
Volatility and Risk
RYTHM has a beta of 9.44, meaning that its stock price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s competitors have a beta of -3.13, meaning that their average stock price is 413% less volatile than the S&P 500.
Summary
RYTHM competitors beat RYTHM on 9 of the 13 factors compared.
RYTHM Company Profile
Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for RYTHM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RYTHM and related companies with MarketBeat.com's FREE daily email newsletter.
